Poxel SA

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Taiho Sends Benz LSD1 Inhibitor Fo

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel

Poxel SA is seeking more Asian marketing deals for its Sumitomo Pharma Co., Ltd. -partnered first-in-class anti-diabetic product Twymeeg in a bid to pay off its debt and enhance its dwindling cash p

Cash-poor Poxel SA is drawing nearer to a key decision about which of its two mid-stage non-alcoholic steatohepatitis candidates to move into Phase III, but positive top-line data reported on 30 Aug